China's Brain Chip Breakthrough: First Commercial BCI Implant

China has taken a significant leap towards global leadership in the brain-computer interface (BCI) market. This week, Chinese neurotechnology firm Neuracle successfully performed the world's first surgical implant of a commercial BCI in a patient who had lost hand mobility due to a spinal cord injury.

The device, named NEO, is a coin-sized implant with eight electrodes. It is surgically placed on the brain's sensorimotor cortex to record electrical signals from imagined hand movements. These signals are then transmitted to a computer, which controls a robotic glove worn by the patient.

NEO received approval from China's National Medical Products Association in March, making it the first invasive BCI to gain commercial use approval from a national regulatory body. This success rivals efforts by Elon Musk's Neuralink, which has also pursued human BCI implants but awaits FDA approval in the U.S.

While invasive implants like NEO and Neuralink's are advancing, other companies are exploring less invasive BCI technologies. Meta's Brain2Qwerty system uses large language models to translate brain activity into text, potentially aiding communication for individuals with neurodegenerative diseases. Meanwhile, Chinese firm BrainCo has developed an AI-powered bionic prosthetic hand.

China's commitment to BCIs is underscored by their inclusion as a core priority in the government's latest five-year plan, alongside other strategic technologies such as quantum computing and AI-powered robots.